Dr Emma Quaranta
Alderley Park, UK – 05 November 2018
Maxwellia, the UK’s only ‘prescription to over the counter (OTC)’ medicines company, has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator, near Manchester. The hires are part of a rapid growth phase for the company, which aims to build on its product pipeline to become the ‘go to’ for switch innovation.
Alexandra Trehane is Maxwellia’s new Head of Innovation and Dr Emma Quaranta is Senior Regulatory Consultant. Both bring significant OTC experience from their previous roles. Alexandra joins from GSK where she worked in the Consumer Healthcare business, while Emma brings a breadth of experience in working with regulators at Bell’s Healthcare.
“We’re delighted to welcome Alexandra and Emma during this exciting period of expansion as we relocate to Alderley Park,” said Anna Maxwell, CEO of Maxwellia. “It is inspiring to be at the heart of a community of innovative and like-minded science professionals as we further develop our portfolio. Growing our team and expert capability will allow us to focus on speed-to-market for our new products, enabling more people to access the information and medicines they need without having to bother their GP.”
The NHS is under unprecedented strain with soaring public demand and severe budget constraints. Minor ailments account for one in five GP consultations in England and cost an estimated £2 billion each year.(1) Many of these consultations could simply be avoided if more of the medicines that currently require a prescription were to become available to buy in pharmacies or supermarkets without a prescription.
“Successfully navigating the changing pharmacy landscape will be challenging but as a small independent company, Maxwellia is perfectly suited to adapt to the environment quickly,” commented Alexandra Trehane, Head of Innovation at Maxwellia. “There is huge potential for growth in the OTC sector and I am thrilled to work for a company destined to play such a key role in helping to reinvigorate the Self Care market and improve public health.”
The value of the UK consumer healthcare market is estimated at £2.47 billion and growing.(2) Switching is a vital means of maintaining the flow of new drugs for Self Care and it is estimated that new switches could add 20% to the UK OTC market by 2030.(3)
1. Self Care: the first step to saving the NHS. PAGB Self Care Forum. 2013
2. PAGB. About Our Industry. https://www.pagb.co.uk/about-us/about-our-industry/Accessed 15 March 2018
3. Maxwellia Estimate
Anna Maxwell, CEO, Maxwellia firstname.lastname@example.org
+44 (0)7778 963 687
Notes to Editors:
Maxwellia is the first dedicated OTC switching company in the UK and is led by a pioneering multi-disciplinary team with over 100 combined years of experience in the field. Its mission is to widen access to more medicines to enable people to look after themselves better. Maxwellia has the strategic and commercial acumen to re-invigorate familiar drug molecules in a different way, safely repurpose them for Self Care and bring new, much-needed medicines to market. The company offers consultancy and capability services to small and mid-sized pharmaceutical companies in the UK/EU who want to switch their own established prescription medicines, and is also investing in its own switch programmes developing new OTC medicines to tackle future Public Health priorities.
About Anna Maxwell MRPharmS
Anna is a pharmacist and author of Switch Dynamics: A practical approach to switching medicines for Self Care. Having conducted in-depth analysis of over 30 switch projects in the UK and EU, and facilitated over 20, including the ground-breaking EU switch of morning-after pill, ellaOne, Anna has an unparalleled understanding of the critical factors necessary for a successful product launch.
Appointments will expedite conversion of prescription medicines to over the counter